79
Participants
Start Date
February 23, 2017
Primary Completion Date
February 25, 2019
Study Completion Date
February 25, 2019
Pimavanserin
Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
Abington Neurological Associates, Ltd., Willow Grove
Clinical Research Unit, Washington D.C.
ANI Neurology, PLLC dba Alzheimer's Memory Center, Charlotte
CHU de Toulouse - Cite de la sante - Gerontople, Toulouse
Quantum Laboratories Inc., Deerfield Beach
Miami Jewish Health Systems, Miami
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton
Collier Neurologic Specialists LLC, Naples
Centro de Atencion Especializada Oroitu, Algorta
Hospital Viamed Montecanal, Zaragoza
Insite Clinical Research, LLC, DeSoto
Pharmaceutical Research Associates, Inc., Salt Lake City
Pacific Clinical Research Network, San Diego
ATP Clinical Research, Inc., Costa Mesa
Neurology Center of North Orange County, Fullerton
Neuro-Pain Medical Center, Fresno
Biomedica Research Group, Santiago
Especialidades Medicas L y S, Santiago
Acadia Hospital, Bangor
Alzheimer's Disease Center, Quincy
Memory Enhancement Center of America, Inc., Eatontown
Bio Behavioral Health, Toms River
Psicomed Estudios Médicos, Antofagasta
Hospital General Universitario de Elche, Elche
Hospital Universitari Mutua de Terrassa, Terrassa
RICE-The Research Institute for the Care of Older People, The RICE Centre, The Royal United Hospital, Bath
West London Cognitive Disorders Treatment & Research Unit, Lakeside Mental Health Unit, West Middlesex University Hosp. Site, Isleworth
Greater Manchester Mental Health NHS Foundation Trust, Manchester
Lead Sponsor
ACADIA Pharmaceuticals Inc.
INDUSTRY